<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01068613</url>
  </required_header>
  <id_info>
    <org_study_id>CQAX028A2201</org_study_id>
    <nct_id>NCT01068613</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Multiple Doses of QAX028 in Chronic Obstructive Pulmonary Disease (COPD) Patients</brief_title>
  <official_title>A Randomized, Double-blind, Double-dummy, Three Period Incomplete Cross-over Study to Evaluate the Safety and Efficacy of Multiple Daily Doses of QAX028 as Compared to Tiotropium Bromide (Positive Control) and Placebo in COPD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will assess the bronchodilator effects of multiple doses of QAX028 at two
      different dose levels when compared to tiotropium and placebo in a COPD population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure: Compare the efficacy of QAX028 at a high dose, as measured by trough forced expiratory volume in 1 second (FEV1), to tiotropium</measure>
    <time_frame>7 days treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the efficacy of QAX028 at a low dose, as measured by trough FEV1, to tiotropium</measure>
    <time_frame>7 days treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure: Compare the efficacy of QAX028 at two dose levels, as measured by trough FEV1, to placebo</measure>
    <time_frame>7 days treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure: Evaluate the safety and tolerability of two dose levels of QAX028 in COPD patients</measure>
    <time_frame>7 days treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure: Evaluate the pharmacokinetics of multiple inhaled does of QAX028</measure>
    <time_frame>7 days treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure: Assess bronchodilatory profile, as measured by FEV1, of multiple inhaled doses of QAX028 in COPD patients</measure>
    <time_frame>7 days treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>QAX028 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>QAX028 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QAX028</intervention_name>
    <description>QAX028 60 mcg via inhalation device</description>
    <arm_group_label>QAX028 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QAX028</intervention_name>
    <description>QAX028 20 mcg via inhalation device</description>
    <arm_group_label>QAX028 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
    <description>Tiotropium via inhalation device</description>
    <arm_group_label>Tiotropium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to QAX028 via inhalation device</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of COPD according to GOLD guidelines

          -  Post-bronchodilator 30%â‰¤FEV1&lt;80% of predicted normal and ost-bronchodilator FEV1/FVC
             &lt;0.7

          -  Smoking history of at least 10 pack years

        Exclusion Criteria:

          -  Requiring oxygen therapy on a daily basis

          -  Exacerbation of airway disease in the 6 weeks prior to screening or between screening
             and dosing

          -  Lung reduction surgery

          -  Respiratory tract infection in the 6 weeks prior to screening

          -  Significant cardiac history

          -  History of asthma with onset of symptoms prior to age 40 years

          -  Active use of certain COPD medications, beta blockers

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Advanced Clinical Research Institute, 1211 W. La Palma Ave</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>CA</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sneeze, Wheeze, &amp; Itch Associates, LLC, 2010 Jacobssen Drive</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>IL61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spartanburg Medical Research, 485 Simuel Road</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>SC 29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Orleans Center for Clinical Research - Knoxville, 1928 Alcoa Highway</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>TN 37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2010</study_first_submitted>
  <study_first_submitted_qc>February 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2010</study_first_posted>
  <disposition_first_submitted>May 2, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>May 2, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 4, 2012</disposition_first_posted>
  <last_update_submitted>May 2, 2012</last_update_submitted>
  <last_update_submitted_qc>May 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Long acting muscarinic antagonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

